PET Radioactive Tracers Market by Product Type, End-Users, and Geography (North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025-2032
Description
Persistence Market Research has recently released a comprehensive report on the global PET Radioactive Tracers Market, providing an in-depth analysis of key market dynamics, including driving forces, emerging trends, opportunities, and challenges. This report offers a detailed understanding of the evolving nuclear medicine landscape and helps stakeholders make well-informed strategic and investment decisions.
Key Insights:
The PET radioactive tracers market encompasses radiopharmaceutical compounds used in positron emission tomography imaging for diagnostic and prognostic purposes across oncology, neurology, cardiology, and infectious disease applications. These tracers, including F-18, C-11, Ga-68, O-15, N-13, and Cu-64, play a critical role in enabling high-resolution functional imaging and early disease detection. Increasing demand for accurate diagnostic imaging, rising cancer incidence, and growing adoption of molecular imaging technologies are driving the market forward. Advancements in tracer development, improved radiochemistry techniques, and expansion of PET imaging infrastructure are further supporting market growth. The market continues to evolve with innovations in targeted radiotracers and expanding clinical applications.
Market Growth Drivers:
The growth of the global PET radioactive tracers market is primarily driven by the increasing prevalence of cancer, neurological disorders, and cardiovascular diseases worldwide. Growing demand for early and precise disease diagnosis has significantly increased the adoption of PET imaging technologies. Advancements in fluorine-18 and gallium-68 based tracers have enhanced diagnostic accuracy, particularly in oncology and neurodegenerative disorders such as Alzheimer’s disease and dementia. Expanding healthcare infrastructure and increasing investments in nuclear medicine facilities are further strengthening market expansion. Additionally, growing awareness among clinicians regarding the clinical benefits of molecular imaging for disease monitoring and treatment planning is accelerating tracer demand across hospitals and specialty diagnostic centers.
Market Restraints:
Despite steady growth, the PET radioactive tracers market faces certain challenges that may restrain its expansion. High costs associated with PET imaging systems, cyclotron facilities, and tracer production limit accessibility in low- and middle-income regions. Short half-life of radioactive isotopes requires complex logistics and proximity to production facilities, creating operational constraints. Regulatory complexities related to radiopharmaceutical approvals and stringent safety requirements may delay product launches and commercialization. Furthermore, limited availability of skilled professionals trained in nuclear medicine and radiochemistry can hinder market growth in emerging markets.
Market Opportunities:
The PET radioactive tracers market offers significant growth opportunities driven by continuous innovation in targeted radiopharmaceutical development and personalized medicine approaches. Increasing research in oncology biomarkers and theranostics is opening new avenues for tracer applications in precision diagnostics. Expansion of PET imaging centers in emerging economies presents substantial growth potential. Growing collaborations between academic research institutes, pharmaceutical companies, and radiopharma manufacturers are expected to accelerate novel tracer development. Additionally, advancements in generator-based isotope production and automation technologies can improve tracer availability and operational efficiency, supporting long-term market expansion.
Key Questions Answered in the Report:
Leading companies in the global PET radioactive tracers market are focusing on expanding radiopharmaceutical portfolios, enhancing production capabilities, and investing in advanced isotope technologies. Strategic partnerships with hospitals, research institutes, and pharmaceutical firms are enabling companies to strengthen clinical adoption and distribution networks. Emphasis on innovation in oncology-specific tracers, automation in radiochemistry processes, and expansion into emerging markets is helping companies maintain competitive differentiation. Investments in research and regulatory approvals for novel PET tracers continue to shape the competitive landscape.
Competitive Analysis:
Key companies operating in the global PET radioactive tracers market include:
By Product
Please Note: It will take 5 business days to complete the report upon order confirmation.
Key Insights:
- PET Radioactive Tracers Market Size (2024): US$ 1,023.70 Mn
- Projected Market Value (2032F): US$ 1,706.7 Mn
- Forecast Growth Rate (CAGR 2024 to 2032): 6.9%
The PET radioactive tracers market encompasses radiopharmaceutical compounds used in positron emission tomography imaging for diagnostic and prognostic purposes across oncology, neurology, cardiology, and infectious disease applications. These tracers, including F-18, C-11, Ga-68, O-15, N-13, and Cu-64, play a critical role in enabling high-resolution functional imaging and early disease detection. Increasing demand for accurate diagnostic imaging, rising cancer incidence, and growing adoption of molecular imaging technologies are driving the market forward. Advancements in tracer development, improved radiochemistry techniques, and expansion of PET imaging infrastructure are further supporting market growth. The market continues to evolve with innovations in targeted radiotracers and expanding clinical applications.
Market Growth Drivers:
The growth of the global PET radioactive tracers market is primarily driven by the increasing prevalence of cancer, neurological disorders, and cardiovascular diseases worldwide. Growing demand for early and precise disease diagnosis has significantly increased the adoption of PET imaging technologies. Advancements in fluorine-18 and gallium-68 based tracers have enhanced diagnostic accuracy, particularly in oncology and neurodegenerative disorders such as Alzheimer’s disease and dementia. Expanding healthcare infrastructure and increasing investments in nuclear medicine facilities are further strengthening market expansion. Additionally, growing awareness among clinicians regarding the clinical benefits of molecular imaging for disease monitoring and treatment planning is accelerating tracer demand across hospitals and specialty diagnostic centers.
Market Restraints:
Despite steady growth, the PET radioactive tracers market faces certain challenges that may restrain its expansion. High costs associated with PET imaging systems, cyclotron facilities, and tracer production limit accessibility in low- and middle-income regions. Short half-life of radioactive isotopes requires complex logistics and proximity to production facilities, creating operational constraints. Regulatory complexities related to radiopharmaceutical approvals and stringent safety requirements may delay product launches and commercialization. Furthermore, limited availability of skilled professionals trained in nuclear medicine and radiochemistry can hinder market growth in emerging markets.
Market Opportunities:
The PET radioactive tracers market offers significant growth opportunities driven by continuous innovation in targeted radiopharmaceutical development and personalized medicine approaches. Increasing research in oncology biomarkers and theranostics is opening new avenues for tracer applications in precision diagnostics. Expansion of PET imaging centers in emerging economies presents substantial growth potential. Growing collaborations between academic research institutes, pharmaceutical companies, and radiopharma manufacturers are expected to accelerate novel tracer development. Additionally, advancements in generator-based isotope production and automation technologies can improve tracer availability and operational efficiency, supporting long-term market expansion.
Key Questions Answered in the Report:
- What are the primary factors driving the growth of the global PET radioactive tracers market?
- Which product types and applications are witnessing the highest adoption across healthcare settings?
- How are advancements in radiopharmaceutical development influencing market dynamics?
- Who are the key players in the PET radioactive tracers market, and what strategies are they adopting to maintain competitiveness?
- What are the future growth trends and regional expansion opportunities through 2032?
Leading companies in the global PET radioactive tracers market are focusing on expanding radiopharmaceutical portfolios, enhancing production capabilities, and investing in advanced isotope technologies. Strategic partnerships with hospitals, research institutes, and pharmaceutical firms are enabling companies to strengthen clinical adoption and distribution networks. Emphasis on innovation in oncology-specific tracers, automation in radiochemistry processes, and expansion into emerging markets is helping companies maintain competitive differentiation. Investments in research and regulatory approvals for novel PET tracers continue to shape the competitive landscape.
Competitive Analysis:
Key companies operating in the global PET radioactive tracers market include:
- Eli Lilly and Company
- Blue Earth Diagnostics
- Lantheus
- Siemens Healthcare Private Limited
- GE Healthcare
- Advanced Accelerator Applications (Novartis)
- University of Lowa HealthCare
- Telix Pharmaceuticals Limited
- Jubilant Radiopharma
- TRASIS
- RadioMedix Inc.
- IBA Radiopharma Solutions
- Piramal Imaging (Life Molecular Imaging)
- Cardinal Health
- DuchemBio, Co., Ltd
By Product
- F-18
- C-11
- Ga-68
- O-15
- N-13
- Cu-64
- Neurological Disorders
- Cancer Diagnosis and Prognosis
- Cardiac Dysfunctions
- Infectious Disease Diagnosis
- Others
- Hospitals
- Specialty Diagnostic Centers
- Cancer Research Centers
- Academic and Research Institutes
- North America
- Latin America
- East Asia
- South Asia and Pacific
- Western Europe
- Eastern Europe
- Central Asia
- Russia and Belarus
- Balkan and Baltic Countries
- Middle East and Africa
Please Note: It will take 5 business days to complete the report upon order confirmation.
Table of Contents
359 Pages
- 1. Executive Summary
- 1.1. Global Market Outlook
- 1.2. Demand Side Trends
- 1.3. Supply Side Trends
- 1.4. Analysis and Recommendations
- 2. Market Overview
- 2.1. Market Coverage / Taxonomy
- 2.2. Market Definition / Scope / Limitations
- 2.3. Inclusion and Exclusions
- 3. Key Market Trends
- 3.1. Key Trends Impacting the Market
- 3.2. Innovation / Development Trends
- 4. Key Success Factors
- 4.1. PET Scanner Installed Base Scenario
- 4.2. Number of PET Scans, By Country
- 4.3. Disease Epidemiology
- 4.4. Product Adoption/Usage Analysis
- 4.5. Regulatory Approval Pathway
- 4.6. Reimbursement Scenario
- 4.7. Technology Advancements
- 4.8. Good Manufacturing Practice (cGMP)
- 4.9. Value Chain Analysis
- 4.10. Quality Standards/Accreditations
- 4.11. PESTEL Analysis
- 4.12. Porter’s Analysis
- 5. Market Background
- 5.1. Macro-Economic Factors
- 5.1.1. Global GDP Outlook
- 5.1.2. Global Healthcare Expenditure Outlook
- 5.1.3. Oncology Spending
- 5.2. Forecast Factors - Relevance & Impact
- 5.2.1. Development of Novel Products
- 5.2.2. Regulatory Imposition
- 5.2.3. Increasing Spending on Targeted Therapies
- 5.2.4. Increasing Prevalence of Cancer
- 5.2.5. Strategic Mergers and Acquisitions among Local Players
- 5.2.6. Rising Awareness towards Development of Disease
- 5.3. Market Dynamics
- 5.3.1. Drivers
- 5.3.2. Restraints
- 5.3.3. Opportunity Analysis
- 6. COVID-19 Crisis Analysis
- 6.1. 2021 Market Scenario
- 6.2. COVID-19 and Impact Analysis
- 6.2.1. By Product
- 6.2.2. By Application
- 6.2.3. By End User
- 6.2.4. By Region
- 7. Global Market Demand (in Value or Size in US$ Mn) Analysis 2019–2024 and Forecast, 2025–2032
- 7.1. Historical Market Value (US$ Mn) Analysis, 2019–2024
- 7.2. Current and Future Market Value (US$ Mn) Projections, 2025–2032
- 7.2.1. Y-o-Y Growth Trend Analysis
- 7.2.2. Absolute $ Opportunity Analysis
- 8. Global Market Analysis 2019–2024 and Forecast 2025–2032, By Product
- 8.1. Introduction / Key Findings
- 8.2. Historical Market Size (US$ Mn) Analysis By Product, 2019–2024
- 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Product, 2025–2032
- 8.3.1. F-18
- 8.3.1.1. Florbetapir
- 8.3.1.2. Florbetaben
- 8.3.1.3. Flutemetamol
- 8.3.1.4. Fludeoxyglucose
- 8.3.1.5. Sodium Fluoride
- 8.3.1.6. Others
- 8.3.2. C-11
- 8.3.2.1. Choline
- 8.3.2.2. Methionine
- 8.3.2.3. Others
- 8.3.3. Ga-68
- 8.3.3.1. DOTA-TOC
- 8.3.3.2. DOTATATE
- 8.3.3.3. DOTANOC
- 8.3.3.4. Others
- 8.3.4. O-15
- 8.3.5. N-13
- 8.3.6. Cu-64
- 8.4. Market Attractiveness Analysis By End User
- 9. Global Market Analysis 2019–2024 and Forecast 2025–2032, By Application
- 9.1. Introduction / Key Findings
- 9.2. Historical Market Size (US$ Mn) Analysis By Application, 2019–2024
- 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Application, 2025–2032
- 9.3.1. Neurological Disorders
- 9.3.1.1. Alzheimer’s Disease
- 9.3.1.2. Dementia
- 9.3.1.3. Others
- 9.3.2. Cancer Diagnosis & Prognosis
- 9.3.2.1. Solid Tumor
- 9.3.2.2. Hematology Tumor
- 9.3.3. Cardiac Dysfunctions
- 9.3.3.1. Myocardial Infarction
- 9.3.3.2. Others
- 9.3.4. Infectious disease Diagnosis
- 9.3.5. Others
- 9.4. Market Attractiveness Analysis By End User
- 10. Global Market Analysis 2019–2024 and Forecast 2025–2032, By End User
- 10.1. Introduction / Key Findings
- 10.2. Historical Market Size (US$ Mn) Analysis By End User, 2019–2024
- 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By End User, 2025–2032
- 10.3.1. Hospitals
- 10.3.2. Speciality Diagnostic Centers
- 10.3.3. Cancer Research Centers
- 10.3.4. Academic & Research Institutes
- 10.4. Market Attractiveness Analysis By End User
- 11. Global Market Analysis 2019–2024 and Forecast 2025–2032, By Region
- 11.1. Introduction
- 11.2. Historical Market Size (US$ Mn) Analysis By Region, 2019–2024
- 11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2025–2032
- 11.3.1. North America
- 11.3.2. Latin America
- 11.3.3. East Asia
- 11.3.4. South Asia & Pacific
- 11.3.5. Western Europe
- 11.3.6. Eastern Europe
- 11.3.7. Central Asia
- 11.3.8. Russia & Belarus
- 11.3.9. Balkan & Baltic Countries
- 11.3.10. Middle East & Africa
- 11.4. Market Attractiveness Analysis By Region
- 12. North America Market Analysis 2019–2024 and Forecast 2025–2032
- 12.1. Introduction
- 12.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019–2024
- 12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025–2032
- 12.3.1. By Country
- 12.3.1.1. U.S.
- 12.3.1.2. Canada
- 12.3.2. By Product
- 12.3.3. By Application
- 12.3.4. By End User
- 12.4. Market Attractiveness Analysis
- 12.4.1. By Country
- 12.4.2. By Product
- 12.4.3. By Application
- 12.4.4. By End User
- 12.5. Key Market Trends
- 12.6. Drivers and Restraints - Impact Analysis
- 12.7. Key Players - Intensity Mapping
- 12.8. Country Level Analysis & Forecast
- 12.8.1. U.S. Market
- 12.8.1.1. Introduction
- 12.8.1.2. Market Analysis and Forecast by Market Taxonomy
- 12.8.1.2.1. By Product
- 12.8.1.2.2. By Application
- 12.8.1.2.3. By End User
- 12.8.2. Canada Market
- 12.8.2.1. Introduction
- 12.8.2.2. Market Analysis and Forecast by Market Taxonomy
- 12.8.2.2.1. By Product
- 12.8.2.2.2. By Application
- 12.8.2.2.3. By End User
- 13. Latin America Market Analysis 2019–2024 and Forecast 2025–2032
- 13.1. Introduction
- 13.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019–2024
- 13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025–2032
- 13.3.1. By Country
- 13.3.1.1. Brazil
- 13.3.1.2. Argentina
- 13.3.1.3. Mexico
- 13.3.1.4. Rest of Latin America
- 13.3.2. By Product
- 13.3.3. By Application
- 13.3.4. By End User
- 13.4. Market Attractiveness Analysis
- 13.4.1. By Country
- 13.4.2. By Product
- 13.4.3. By Application
- 13.4.4. By End User
- 13.5. Key Market Trends
- 13.6. Drivers and Restraints - Impact Analysis
- 13.7. Key Players - Intensity Mapping
- 13.8. Country Level Analysis & Forecast
- 13.8.1. Brazil Market
- 13.8.1.1. Introduction
- 13.8.1.2. Market Analysis and Forecast by Market Taxonomy
- 13.8.1.2.1. By Product
- 13.8.1.2.2. By Application
- 13.8.1.2.3. By End User
- 13.8.2. Argentina Market
- 13.8.2.1. Introduction
- 13.8.2.2. Market Analysis and Forecast by Market Taxonomy
- 13.8.2.2.1. By Product
- 13.8.2.2.2. By Application
- 13.8.2.2.3. By End User
- 13.8.3. Mexico Market
- 13.8.3.1. Introduction
- 13.8.3.2. Market Analysis and Forecast by Market Taxonomy
- 13.8.3.2.1. By Product
- 13.8.3.2.2. By Application
- 13.8.3.2.3. By End User
- 14. East Asia Market Analysis 2019–2024 and Forecast 2025–2032
- 14.1. Introduction
- 14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019–2024
- 14.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025–2032
- 14.3.1. By Country
- 14.3.1.1. China
- 14.3.1.2. Japan
- 14.3.1.3. South Korea
- 14.3.2. By Product
- 14.3.3. By Application
- 14.3.4. By End User
- 14.4. Market Attractiveness Analysis
- 14.4.1. By Country
- 14.4.2. By Product
- 14.4.3. By Application
- 14.4.4. By End User
- 14.5. Key Market Trends
- 14.6. Drivers and Restraints - Impact Analysis
- 14.7. Key Players - Intensity Mapping
- 14.8. Country Level Analysis & Forecast
- 14.8.1. China Market
- 14.8.1.1. Introduction
- 14.8.1.2. Market Analysis and Forecast by Market Taxonomy
- 14.8.1.2.1. By Product
- 14.8.1.2.2. By Application
- 14.8.1.2.3. By End User
- 14.8.2. Japan Market
- 14.8.2.1. Introduction
- 14.8.2.2. Market Analysis and Forecast by Market Taxonomy
- 14.8.2.2.1. By Product
- 14.8.2.2.2. By Application
- 14.8.2.2.3. By End User
- 14.8.3. South Korea Market
- 14.8.3.1. Introduction
- 14.8.3.2. Market Analysis and Forecast by Market Taxonomy
- 14.8.3.2.1. By Product
- 14.8.3.2.2. By Application
- 14.8.3.2.3. By End User
- 15. South Asia & Pacific Market Analysis 2019–2024 and Forecast 2025–2032
- 15.1. Introduction
- 15.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019–2024
- 15.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025–2032
- 15.3.1. By Country
- 15.3.1.1. India
- 15.3.1.2. Indonesia
- 15.3.1.3. Thailand
- 15.3.1.4. Philippines
- 15.3.1.5. Malaysia
- 15.3.1.6. Vietnam
- 15.3.1.7. Rest of ASEAN
- 15.3.1.8. Australia & New Zealand
- 15.3.2. By Product
- 15.3.3. By Application
- 15.3.4. By End User
- 15.4. Market Attractiveness Analysis
- 15.4.1. By Country
- 15.4.2. By Product
- 15.4.3. By Application
- 15.4.4. By End User
- 15.5. Key Market Trends
- 15.6. Drivers and Restraints - Impact Analysis
- 15.7. Key Players - Intensity Mapping
- 15.8. Country Level Analysis & Forecast
- 15.8.1. India Market
- 15.8.1.1. Introduction
- 15.8.1.2. Market Analysis and Forecast by Market Taxonomy
- 15.8.1.2.1. By Product
- 15.8.1.2.2. By Application
- 15.8.1.2.3. By End User
- 15.8.2. Indonesia Market
- 15.8.2.1. Introduction
- 15.8.2.2. Market Analysis and Forecast by Market Taxonomy
- 15.8.2.2.1. By Product
- 15.8.2.2.2. By Application
- 15.8.2.2.3. By End User
- 15.8.3. Thailand Market
- 15.8.3.1. Introduction
- 15.8.3.2. Market Analysis and Forecast by Market Taxonomy
- 15.8.3.2.1. By Product
- 15.8.3.2.2. By Application
- 15.8.3.2.3. By End User
- 15.8.4. Philippines Market
- 15.8.4.1. Introduction
- 15.8.4.2. Market Analysis and Forecast by Market Taxonomy
- 15.8.4.2.1. By Product
- 15.8.4.2.2. By Application
- 15.8.4.2.3. By End User
- 15.8.5. Malaysia Market
- 15.8.5.1. Introduction
- 15.8.5.2. Market Analysis and Forecast by Market Taxonomy
- 15.8.5.2.1. By Product
- 15.8.5.2.2. By Application
- 15.8.5.2.3. By End User
- 15.8.6. Vietnam Market
- 15.8.6.1. Introduction
- 15.8.6.2. Market Analysis and Forecast by Market Taxonomy
- 15.8.6.2.1. By Product
- 15.8.6.2.2. By Application
- 15.8.6.2.3. By End User
- 15.8.7. Australia & New Zealand Market
- 15.8.7.1. Introduction
- 15.8.7.2. Market Analysis and Forecast by Market Taxonomy
- 15.8.7.2.1. By Product
- 15.8.7.2.2. By Application
- 15.8.7.2.3. By End User
- 16. Western Europe Market Analysis 2019–2024 and Forecast 2025–2032
- 16.1. Introduction
- 16.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019–2024
- 16.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025–2032
- 16.3.1. By Country
- 16.3.1.1. Germany
- 16.3.1.2. France
- 16.3.1.3. Spain
- 16.3.1.4. Italy
- 16.3.1.5. BENELUX
- 16.3.1.6. Nordic Countries
- 16.3.1.7. United Kingdom
- 16.3.2. By Product
- 16.3.3. By Application
- 16.3.4. By End User
- 16.4. Market Attractiveness Analysis
- 16.4.1. By Country
- 16.4.2. By Product
- 16.4.3. By Application
- 16.4.4. By End User
- 16.5. Key Market Trends
- 16.6. Drivers and Restraints - Impact Analysis
- 16.7. Key Players - Intensity Mapping
- 16.8. Country Level Analysis & Forecast
- 16.8.1. Germany Market
- 16.8.1.1. Introduction
- 16.8.1.2. Market Analysis and Forecast by Market Taxonomy
- 16.8.1.2.1. By Product
- 16.8.1.2.2. By Application
- 16.8.1.2.3. By End User
- 16.8.2. France Market
- 16.8.2.1. Introduction
- 16.8.2.2. Market Analysis and Forecast by Market Taxonomy
- 16.8.2.2.1. By Product
- 16.8.2.2.2. By Application
- 16.8.2.2.3. By End User
- 16.8.3. Spain Market
- 16.8.3.1. Introduction
- 16.8.3.2. Market Analysis and Forecast by Market Taxonomy
- 16.8.3.2.1. By Product
- 16.8.3.2.2. By Application
- 16.8.3.2.3. By End User
- 16.8.4. Italy Market
- 16.8.4.1. Introduction
- 16.8.4.2. Market Analysis and Forecast by Market Taxonomy
- 16.8.4.2.1. By Product
- 16.8.4.2.2. By Application
- 16.8.4.2.3. By End User
- 16.8.5. BENULUX Market
- 16.8.5.1. Introduction
- 16.8.5.2. Market Analysis and Forecast by Market Taxonomy
- 16.8.5.2.1. By Product
- 16.8.5.2.2. By Application
- 16.8.5.2.3. By End User
- 16.8.6. Nordic Countries Market
- 16.8.6.1. Introduction
- 16.8.6.2. Market Analysis and Forecast by Market Taxonomy
- 16.8.6.2.1. By Product
- 16.8.6.2.2. By Application
- 16.8.6.2.3. By End User
- 16.8.7. U.K. Market
- 16.8.7.1. Introduction
- 16.8.7.2. Market Analysis and Forecast by Market Taxonomy
- 16.8.7.2.1. By Product
- 16.8.7.2.2. By Application
- 16.8.7.2.3. By End User
- 17. Eastern Europe Market Analysis 2019–2024 and Forecast 2025–2032
- 17.1. Introduction
- 17.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019–2024
- 17.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025–2032
- 17.3.1. By Country
- 17.3.1.1. Poland
- 17.3.1.2. Hungary
- 17.3.1.3. Romania
- 17.3.1.4. Czech Republic
- 17.3.1.5. Rest of Eastern Europe
- 17.3.2. By Product
- 17.3.3. By Application
- 17.3.4. By End User
- 17.4. Market Attractiveness Analysis
- 17.4.1. By Country
- 17.4.2. By Product
- 17.4.3. By Application
- 17.4.4. By End User
- 17.5. Key Market Trends
- 17.6. Drivers and Restraints - Impact Analysis
- 17.7. Key Players - Intensity Mapping
- 17.8. Country Level Analysis & Forecast
- 17.8.1. Poland Market
- 17.8.1.1. Introduction
- 17.8.1.2. Market Analysis and Forecast by Market Taxonomy
- 17.8.1.2.1. By Product
- 17.8.1.2.2. By Application
- 17.8.1.2.3. By End User
- 17.8.2. Hungary Market
- 17.8.2.1. Introduction
- 17.8.2.2. Market Analysis and Forecast by Market Taxonomy
- 17.8.2.2.1. By Product
- 17.8.2.2.2. By Application
- 17.8.2.2.3. By End User
- 17.8.3. Romania Market
- 17.8.3.1. Introduction
- 17.8.3.2. Market Analysis and Forecast by Market Taxonomy
- 17.8.3.2.1. By Product
- 17.8.3.2.2. By Application
- 17.8.3.2.3. By End User
- 17.8.4. Czech Republic Market
- 17.8.4.1. Introduction
- 17.8.4.2. Market Analysis and Forecast by Market Taxonomy
- 17.8.4.2.1. By Product
- 17.8.4.2.2. By Application
- 17.8.4.2.3. By End User
- 18. Central Asia Market Analysis 2019–2024 and Forecast 2025–2032
- 18.1. Introduction
- 18.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019–2024
- 18.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025–2032
- 18.3.1. By Product
- 18.3.2. By Application
- 18.3.3. By End User
- 18.4. Market Attractiveness Analysis
- 18.4.1. By Product
- 18.4.2. By Application
- 18.4.3. By End User
- 18.5. Key Market Trends
- 18.6. Drivers and Restraints - Impact Analysis
- 18.7. Key Players - Intensity Mapping
- 19. Russia & Belarus Market Analysis 2019–2024 and Forecast 2025–2032
- 19.1. Introduction
- 19.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019–2024
- 19.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025–2032
- 19.3.1. By Product
- 19.3.2. By Application
- 19.3.3. By End User
- 19.4. Market Attractiveness Analysis
- 19.4.1. By Product
- 19.4.2. By Application
- 19.4.3. By End User
- 19.5. Key Market Trends
- 19.6. Drivers and Restraints - Impact Analysis
- 19.7. Key Players - Intensity Mapping
- 20. Balkan & Baltic Countries Asia Market Analysis 2019–2024 and Forecast 2025–2032
- 20.1. Introduction
- 20.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019–2024
- 20.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025–2032
- 20.3.1. By Product
- 20.3.2. By Application
- 20.3.3. By End User
- 20.4. Market Attractiveness Analysis
- 20.4.1. By Product
- 20.4.2. By Application
- 20.4.3. By End User
- 20.5. Key Market Trends
- 20.6. Drivers and Restraints - Impact Analysis
- 20.7. Key Players - Intensity Mapping
- 21. Middle East and Africa (MEA) Market Analysis 2019–2024 and Forecast 2025–2032
- 21.1. Introduction
- 21.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019–2024
- 21.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025–2032
- 21.3.1. By Country
- 21.3.1.1. GCC Countries
- 21.3.1.2. Kingdom of Saudi Arabia
- 21.3.1.3. Türkiye
- 21.3.1.4. Northern Africa
- 21.3.1.5. South Africa
- 21.3.1.6. Israel
- 21.3.2. By Product
- 21.3.3. By Application
- 21.3.4. By End User
- 21.4. Market Attractiveness Analysis
- 21.4.1. By Country
- 21.4.2. By Product
- 21.4.3. By Application
- 21.4.4. By End User
- 21.5. Key Market Trends
- 21.6. Drivers and Restraints - Impact Analysis
- 21.7. Key Players - Intensity Mapping
- 21.8. Country Level Analysis & Forecast
- 21.8.1. GCC Countries Market
- 21.8.1.1. Introduction
- 21.8.1.2. Market Analysis and Forecast by Market Taxonomy
- 21.8.1.2.1. By Product
- 21.8.1.2.2. By Application
- 21.8.1.2.3. By End User
- 21.8.2. Kingdom of Saudi Arabia Market
- 21.8.2.1. Introduction
- 21.8.2.2. Market Analysis and Forecast by Market Taxonomy
- 21.8.2.2.1. By Product
- 21.8.2.2.2. By Application
- 21.8.2.2.3. By End User
- 21.8.3. Türkiye Market
- 21.8.3.1. Introduction
- 21.8.3.2. Market Analysis and Forecast by Market Taxonomy
- 21.8.3.2.1. By Product
- 21.8.3.2.2. By Application
- 21.8.3.2.3. By End User
- 21.8.4. Northern Africa Market
- 21.8.4.1. Introduction
- 21.8.4.2. Market Analysis and Forecast by Market Taxonomy
- 21.8.4.2.1. By Product
- 21.8.4.2.2. By Application
- 21.8.4.2.3. By End User
- 21.8.5. South Africa Market
- 21.8.5.1. Introduction
- 21.8.5.2. Market Analysis and Forecast by Market Taxonomy
- 21.8.5.2.1. By Product
- 21.8.5.2.2. By Application
- 21.8.5.2.3. By End User
- 21.8.6. Israel Market
- 21.8.6.1. Introduction
- 21.8.6.2. Market Analysis and Forecast by Market Taxonomy
- 21.8.6.2.1. By Product
- 21.8.6.2.2. By Application
- 21.8.6.2.3. By End User
- 22. Market Structure Analysis
- 22.1. Market Analysis by Tier of Companies
- 22.2. Market Share Analysis of Top Players
- 22.3. Market Presence Analysis
- 22.3.1. Regional footprint of Players
- 22.3.2. Platform Type foot print by Players
- 22.3.3. Channel Foot Print by Players
- 23. Competition Analysis
- 23.1. Competition Dashboard
- 23.2. Competition Benchmarking
- 23.3. Competition Deep Dive
- 23.3.1. Eli Lilly and Company
- 23.3.1.1. Company Overview
- 23.3.1.2. Product Portfolio
- 23.3.1.3. Sales Footprint
- 23.3.1.4. Key Financials
- 23.3.1.5. SWOT Analysis
- 23.3.1.6. Key Developments
- 23.3.1.7. Strategy Overview
- 23.3.1.7.1. Channel Strategy
- 23.3.1.7.2. Marketing Strategy
- 23.3.1.7.3. Product Strategy
- 23.3.2. Blue Earth Diagnostics
- 23.3.2.1. Company Overview
- 23.3.2.2. Product Portfolio
- 23.3.2.3. Sales Footprint
- 23.3.2.4. Key Financials
- 23.3.2.5. SWOT Analysis
- 23.3.2.6. Key Developments
- 23.3.2.7. Strategy Overview
- 23.3.2.7.1. Channel Strategy
- 23.3.2.7.2. Marketing Strategy
- 23.3.2.7.3. Product Strategy
- 23.3.3. Lantheus
- 23.3.3.1. Company Overview
- 23.3.3.2. Product Portfolio
- 23.3.3.3. Sales Footprint
- 23.3.3.4. Key Financials
- 23.3.3.5. SWOT Analysis
- 23.3.3.6. Key Developments
- 23.3.3.7. Strategy Overview
- 23.3.3.7.1. Channel Strategy
- 23.3.3.7.2. Marketing Strategy
- 23.3.3.7.3. Product Strategy
- 23.3.4. Siemens Healthcare Private Limited
- 23.3.4.1. Company Overview
- 23.3.4.2. Product Portfolio
- 23.3.4.3. Sales Footprint
- 23.3.4.4. Key Financials
- 23.3.4.5. SWOT Analysis
- 23.3.4.6. Key Developments
- 23.3.4.7. Strategy Overview
- 23.3.4.7.1. Channel Strategy
- 23.3.4.7.2. Marketing Strategy
- 23.3.4.7.3. Product Strategy
- 23.3.5. GE Healthcare
- 23.3.5.1. Company Overview
- 23.3.5.2. Product Portfolio
- 23.3.5.3. Sales Footprint
- 23.3.5.4. Key Financials
- 23.3.5.5. SWOT Analysis
- 23.3.5.6. Key Developments
- 23.3.5.7. Strategy Overview
- 23.3.5.7.1. Channel Strategy
- 23.3.5.7.2. Marketing Strategy
- 23.3.5.7.3. Product Strategy
- 23.3.6. Advanced Accelerator Applications (Novartis)
- 23.3.6.1. Company Overview
- 23.3.6.2. Product Portfolio
- 23.3.6.3. Sales Footprint
- 23.3.6.4. Key Financials
- 23.3.6.5. SWOT Analysis
- 23.3.6.6. Key Developments
- 23.3.6.7. Strategy Overview
- 23.3.6.7.1. Channel Strategy
- 23.3.6.7.2. Marketing Strategy
- 23.3.6.7.3. Product Strategy
- 23.3.7. University of Lowa HealthCare
- 23.3.7.1. Company Overview
- 23.3.7.2. Product Portfolio
- 23.3.7.3. Sales Footprint
- 23.3.7.4. Key Financials
- 23.3.7.5. SWOT Analysis
- 23.3.7.6. Key Developments
- 23.3.7.7. Strategy Overview
- 23.3.7.7.1. Channel Strategy
- 23.3.7.7.2. Marketing Strategy
- 23.3.7.7.3. Product Strategy
- 23.3.8. Telix Pharmaceuticals Limited
- 23.3.8.1. Company Overview
- 23.3.8.2. Product Portfolio
- 23.3.8.3. Sales Footprint
- 23.3.8.4. Key Financials
- 23.3.8.5. SWOT Analysis
- 23.3.8.6. Key Developments
- 23.3.8.7. Strategy Overview
- 23.3.8.7.1. Channel Strategy
- 23.3.8.7.2. Marketing Strategy
- 23.3.8.7.3. Product Strategy
- 23.3.9. Jubilant Radiopharma
- 23.3.9.1. Company Overview
- 23.3.9.2. Product Portfolio
- 23.3.9.3. Sales Footprint
- 23.3.9.4. Key Financials
- 23.3.9.5. SWOT Analysis
- 23.3.9.6. Key Developments
- 23.3.9.7. Strategy Overview
- 23.3.9.7.1. Channel Strategy
- 23.3.9.7.2. Marketing Strategy
- 23.3.9.7.3. Product Strategy
- 23.3.10. TRASIS
- 23.3.10.1. Company Overview
- 23.3.10.2. Product Portfolio
- 23.3.10.3. Sales Footprint
- 23.3.10.4. Key Financials
- 23.3.10.5. SWOT Analysis
- 23.3.10.6. Key Developments
- 23.3.10.7. Strategy Overview
- 23.3.10.7.1. Channel Strategy
- 23.3.10.7.2. Marketing Strategy
- 23.3.10.7.3. Product Strategy
- 23.3.11. RadioMedix Inc.
- 23.3.11.1. Company Overview
- 23.3.11.2. Product Portfolio
- 23.3.11.3. Sales Footprint
- 23.3.11.4. Key Financials
- 23.3.11.5. SWOT Analysis
- 23.3.11.6. Key Developments
- 23.3.11.7. Strategy Overview
- 23.3.11.7.1. Channel Strategy
- 23.3.11.7.2. Marketing Strategy
- 23.3.11.7.3. Product Strategy
- 23.3.12. IBA Radiopharma Solutions
- 23.3.12.1. Company Overview
- 23.3.12.2. Product Portfolio
- 23.3.12.3. Sales Footprint
- 23.3.12.4. Key Financials
- 23.3.12.5. SWOT Analysis
- 23.3.12.6. Key Developments
- 23.3.12.7. Strategy Overview
- 23.3.12.7.1. Channel Strategy
- 23.3.12.7.2. Marketing Strategy
- 23.3.12.7.3. Product Strategy
- 23.3.13. Piramal Imaging (Life Molecular Imaging)
- 23.3.13.1. Company Overview
- 23.3.13.2. Product Portfolio
- 23.3.13.3. Sales Footprint
- 23.3.13.4. Key Financials
- 23.3.13.5. SWOT Analysis
- 23.3.13.6. Key Developments
- 23.3.13.7. Strategy Overview
- 23.3.13.7.1. Channel Strategy
- 23.3.13.7.2. Marketing Strategy
- 23.3.13.7.3. Product Strategy
- 23.3.14. Cardinal Health
- 23.3.14.1. Company Overview
- 23.3.14.2. Product Portfolio
- 23.3.14.3. Sales Footprint
- 23.3.14.4. Key Financials
- 23.3.14.5. SWOT Analysis
- 23.3.14.6. Key Developments
- 23.3.14.7. Strategy Overview
- 23.3.14.7.1. Channel Strategy
- 23.3.14.7.2. Marketing Strategy
- 23.3.14.7.3. Product Strategy
- 23.3.15. DuchemBio, Co., Ltd
- 23.3.15.1. Company Overview
- 23.3.15.2. Product Portfolio
- 23.3.15.3. Sales Footprint
- 23.3.15.4. Key Financials
- 23.3.15.5. SWOT Analysis
- 23.3.15.6. Key Developments
- 23.3.15.7. Strategy Overview
- 23.3.15.7.1. Channel Strategy
- 23.3.15.7.2. Marketing Strategy
- 23.3.15.7.3. Product Strategy
- 24. Assumptions and Acronyms Used
- 25. Research Methodology
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.

